PMID- 36439295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221129 IS - 1178-7007 (Print) IS - 1178-7007 (Electronic) IS - 1178-7007 (Linking) VI - 15 DP - 2022 TI - Lower Visceral Fat Area in Patients with Type 2 Diabetic Peripheral Neuropathy. PG - 3639-3654 LID - 10.2147/DMSO.S388330 [doi] AB - OBJECTIVE: There is preliminary evidence that visceral fat area (VFA) was associated with the presence of type 2 diabetic peripheral neuropathy (DPN) in the Korean population; however, no studies have reported the association in Chinese population. The purpose of this study was to explore the possible correlation of VFA with DPN in such a population. METHODS: A total of 2498 hospitalized patients with type 2 diabetes mellitus (T2DM) undergone VFA measurement, and were divided into DPN group (n=900) and non-DPN group (n=1594). The association of VFA with the presence of DPN was evaluated by correlation and multiple logistic regression analyses, generalized additive model with a smooth curve fitting, and receiver operating characteristic (ROC) curve analysis. RESULTS: The VFA was significantly lower in the DPN group than in the non-DPN group (P < 0.001). VFA was significantly and positively associated with sural nerve conduction velocity (SNCV) and amplitude potential (SNAP) and negatively associated with the presence of DPN (all P< 0.001); there was no significant difference in the curve fitting (P = 0.344). Multivariate logistic regression analysis showed that the risk of presence of DPN decreased progressively across the VFA quartiles (P for trend < 0.001) and was significantly lower in patients in the highest VFA quartile than in those in the lowest quartile (OR: 0.382, 95% CI 0.151-0.968, P< 0.001) after multivariate adjustment. The ROC analysis revealed that the best cut-off value of VFA for predicting the presence of DPN was 50.5cm(2) (sensitivity 84.40%; specificity 34.00%). CONCLUSION: These results suggest that lower VFA level may be associated with increased risk of the presence of DPN in T2DM patients. CI - (c) 2022 Wu et al. FAU - Wu, Yuru AU - Wu Y AUID- ORCID: 0000-0003-4432-2338 AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Wan, Qin AU - Wan Q AUID- ORCID: 0000-0002-3498-0399 AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Xu, Yong AU - Xu Y AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Li, Jia AU - Li J AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Li, Ke AU - Li K AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Zhang, Zhihong AU - Zhang Z AD - Department of General Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. FAU - Tang, Qian AU - Tang Q AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Miao, Ying AU - Miao Y AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Yan, Pijun AU - Yan P AUID- ORCID: 0000-0001-6692-2401 AD - Department of Endocrinology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20221121 PL - New Zealand TA - Diabetes Metab Syndr Obes JT - Diabetes, metabolic syndrome and obesity : targets and therapy JID - 101515585 PMC - PMC9694982 OTO - NOTNLM OT - Chinese population OT - diabetic peripheral neuropathy OT - sural nerve amplitude potential OT - sural nerve conduction velocity OT - visceral fat area COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/29 06:00 MHDA- 2022/11/29 06:01 PMCR- 2022/11/21 CRDT- 2022/11/28 04:34 PHST- 2022/09/03 00:00 [received] PHST- 2022/11/10 00:00 [accepted] PHST- 2022/11/28 04:34 [entrez] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/29 06:01 [medline] PHST- 2022/11/21 00:00 [pmc-release] AID - 388330 [pii] AID - 10.2147/DMSO.S388330 [doi] PST - epublish SO - Diabetes Metab Syndr Obes. 2022 Nov 21;15:3639-3654. doi: 10.2147/DMSO.S388330. eCollection 2022.